Affinity DataKi: 0.300nMAssay Description:Binding affinity to kappa opioid receptorMore data for this Ligand-Target Pair
Affinity DataKi: 0.5nMAssay Description:Binding affinity to kappa opioid receptorMore data for this Ligand-Target Pair
Affinity DataKi: 0.900nMAssay Description:Binding affinity to kappa opioid receptorMore data for this Ligand-Target Pair
Affinity DataKi: 40nMAssay Description:Binding affinity to kappa opioid receptorMore data for this Ligand-Target Pair
Affinity DataKi: 75nMAssay Description:Binding affinity to kappa opioid receptorMore data for this Ligand-Target Pair
Affinity DataKi: 146nMAssay Description:Binding affinity to kappa opioid receptorMore data for this Ligand-Target Pair
TargetMetabotropic glutamate receptor 5(Homo sapiens (Human))
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 250nMAssay Description:Displacement of [3H]-MPEP from human mGluR5More data for this Ligand-Target Pair
TargetMetabotropic glutamate receptor 5(Homo sapiens (Human))
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 2.37E+3nMAssay Description:Displacement of [3H]-MPEP from human mGluR5More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.140nMAssay Description:Inhibition of human ERGMore data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.25nMAssay Description:Inhibition of human ERGMore data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.260nMAssay Description:Inhibition of human ERGMore data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.380nMAssay Description:Inhibition of human ERGMore data for this Ligand-Target Pair
TargetMitogen-activated protein kinase 11/12/13/14(Homo sapiens (Human))
Procter and Gamble Pharmaceuticals
Curated by ChEMBL
Procter and Gamble Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.400nMAssay Description:Inhibition of LPS-stimulated p38-related TNF-alpha production in human peripheral blood mononuclear cells (PBMC)More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.430nMAssay Description:Inhibition of human ERGMore data for this Ligand-Target Pair
Affinity DataIC50: 0.5nMAssay Description:Antagonist activity at human kappa opioid receptor assessed as inhibition of dynorphin A-induced [35S]GTPgammaS bindingMore data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.520nMAssay Description:Inhibition of human ERGMore data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.610nMAssay Description:Inhibition of human ERGMore data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.620nMAssay Description:Inhibition of human ERGMore data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.620nMAssay Description:Inhibition of human ERGMore data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.720nMAssay Description:Inhibition of human ERGMore data for this Ligand-Target Pair
TargetMitogen-activated protein kinase 11/12/13/14(Homo sapiens (Human))
Procter and Gamble Pharmaceuticals
Curated by ChEMBL
Procter and Gamble Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.800nMAssay Description:Inhibition of LPS-stimulated p38-related IL1-beta production in human peripheral blood mononuclear cells (PBMC)More data for this Ligand-Target Pair
Affinity DataIC50: 0.834nMAssay Description:The H3 binding assay was/can be used to evaluate the ability of at least one compound in accordance with formula I, Ia, Ib, and/or Ic to inhibit [3H]...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.950nMAssay Description:Inhibition of human ERGMore data for this Ligand-Target Pair
TargetSodium- and chloride-dependent glycine transporter 1(Homo sapiens (Human))
Astrazeneca
Curated by ChEMBL
Astrazeneca
Curated by ChEMBL
Affinity DataIC50: 1nMAssay Description:Inhibition of recombinant human GlyT1 expressed in CHO cells assessed as reduction in [3H]glycine uptake pretreated for 15 mins followed by [3H]glyci...More data for this Ligand-Target Pair
TargetSodium- and chloride-dependent glycine transporter 1(Homo sapiens (Human))
Astrazeneca
Curated by ChEMBL
Astrazeneca
Curated by ChEMBL
Affinity DataIC50: 1nMAssay Description:Inhibition of recombinant human GlyT1 expressed in CHO cells assessed as reduction in [3H]glycine uptake pretreated for 15 mins followed by [3H]glyci...More data for this Ligand-Target Pair
TargetSodium- and chloride-dependent glycine transporter 1(Homo sapiens (Human))
Astrazeneca
Curated by ChEMBL
Astrazeneca
Curated by ChEMBL
Affinity DataIC50: 1nMAssay Description:Inhibition of recombinant human GlyT1 expressed in CHO cells assessed as reduction in [3H]glycine uptake pretreated for 15 mins followed by [3H]glyci...More data for this Ligand-Target Pair
TargetSodium- and chloride-dependent glycine transporter 1(Homo sapiens (Human))
Astrazeneca
Curated by ChEMBL
Astrazeneca
Curated by ChEMBL
Affinity DataIC50: 1nMAssay Description:Inhibition of recombinant human GlyT1 expressed in CHO cells assessed as reduction in [3H]glycine uptake pretreated for 15 mins followed by [3H]glyci...More data for this Ligand-Target Pair
TargetSodium- and chloride-dependent glycine transporter 1(Homo sapiens (Human))
Astrazeneca
Curated by ChEMBL
Astrazeneca
Curated by ChEMBL
Affinity DataIC50: 1nMAssay Description:Inhibition of recombinant human GlyT1 expressed in CHO cells assessed as reduction in [3H]glycine uptake pretreated for 15 mins followed by [3H]glyci...More data for this Ligand-Target Pair
TargetSodium- and chloride-dependent glycine transporter 1(Homo sapiens (Human))
Astrazeneca
Curated by ChEMBL
Astrazeneca
Curated by ChEMBL
Affinity DataIC50: 1nMAssay Description:Inhibition of recombinant human GlyT1 expressed in CHO cells assessed as reduction in [3H]glycine uptake pretreated for 15 mins followed by [3H]glyci...More data for this Ligand-Target Pair
Affinity DataIC50: 1.37nMAssay Description:The H3 binding assay was/can be used to evaluate the ability of at least one compound in accordance with formula I, Ia, Ib, and/or Ic to inhibit [3H]...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 1.5nMAssay Description:Inhibition of human ERGMore data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 1.60nMAssay Description:Inhibition of human ERGMore data for this Ligand-Target Pair
Affinity DataIC50: 1.63nMAssay Description:The H3 binding assay was/can be used to evaluate the ability of at least one compound in accordance with formula I, Ia, Ib, and/or Ic to inhibit [3H]...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 1.80nMAssay Description:Inhibition of human ERGMore data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 1.90nMAssay Description:Inhibition of human ERGMore data for this Ligand-Target Pair
TargetMitogen-activated protein kinase 11/12/13/14(Homo sapiens (Human))
Procter and Gamble Pharmaceuticals
Curated by ChEMBL
Procter and Gamble Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 2nMAssay Description:Inhibitory activity against LPS-stimulated TNF-alpha production in human monocytic cells (THP-1)More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 2nMAssay Description:Inhibition of human ERGMore data for this Ligand-Target Pair
TargetSodium- and chloride-dependent glycine transporter 1(Homo sapiens (Human))
Astrazeneca
Curated by ChEMBL
Astrazeneca
Curated by ChEMBL
Affinity DataIC50: 2nMAssay Description:Inhibition of recombinant human GlyT1 expressed in CHO cells assessed as reduction in [3H]glycine uptake pretreated for 15 mins followed by [3H]glyci...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase Lck(Homo sapiens (Human))
Procter And Gamble Pharmaceuticals
Curated by ChEMBL
Procter And Gamble Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 2nMAssay Description:Inhibition of human recombinant Lck in presence of 10 mM ATPMore data for this Ligand-Target Pair
Affinity DataIC50: 2.10nMAssay Description:Antagonist activity at human kappa opioid receptor assessed as inhibition of dynorphin A-induced [35S]GTPgammaS bindingMore data for this Ligand-Target Pair
Affinity DataIC50: 2.10nMAssay Description:Antagonist activity at human kappa opioid receptor expressed in HEK cells assessed as inhibition of dynorphin A-induced [35S]GTPgammaS bindingMore data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 2.80nMAssay Description:Inhibition of human ERGMore data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 2.80nMAssay Description:Inhibition of human ERGMore data for this Ligand-Target Pair
TargetTyrosine-protein kinase Lck(Homo sapiens (Human))
Procter And Gamble Pharmaceuticals
Curated by ChEMBL
Procter And Gamble Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 3nMAssay Description:Inhibition of human recombinant Lck by ProFlour assayMore data for this Ligand-Target Pair
TargetSodium- and chloride-dependent glycine transporter 1(Homo sapiens (Human))
Astrazeneca
Curated by ChEMBL
Astrazeneca
Curated by ChEMBL
Affinity DataIC50: 3nMAssay Description:Inhibition of recombinant human GlyT1 expressed in CHO cells assessed as reduction in [3H]glycine uptake pretreated for 15 mins followed by [3H]glyci...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase Lck(Homo sapiens (Human))
Procter And Gamble Pharmaceuticals
Curated by ChEMBL
Procter And Gamble Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 3nMAssay Description:Inhibition of human recombinant Lck by ProFlour assayMore data for this Ligand-Target Pair
TargetTyrosine-protein kinase Lck(Homo sapiens (Human))
Procter And Gamble Pharmaceuticals
Curated by ChEMBL
Procter And Gamble Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 3nMAssay Description:Inhibition of human recombinant Lck by ProFlour assayMore data for this Ligand-Target Pair
TargetSodium- and chloride-dependent glycine transporter 1(Homo sapiens (Human))
Astrazeneca
Curated by ChEMBL
Astrazeneca
Curated by ChEMBL
Affinity DataIC50: 3nMAssay Description:Inhibition of recombinant human GlyT1 expressed in CHO cells assessed as reduction in [3H]glycine uptake pretreated for 15 mins followed by [3H]glyci...More data for this Ligand-Target Pair
TargetSodium- and chloride-dependent glycine transporter 1(Homo sapiens (Human))
Astrazeneca
Curated by ChEMBL
Astrazeneca
Curated by ChEMBL
Affinity DataIC50: 3nMAssay Description:Inhibition of recombinant human GlyT1 expressed in CHO cells assessed as reduction in [3H]glycine uptake pretreated for 15 mins followed by [3H]glyci...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase 11/12/13/14(Homo sapiens (Human))
Procter and Gamble Pharmaceuticals
Curated by ChEMBL
Procter and Gamble Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 3nMAssay Description:Inhibitory activity against LPS-stimulated TNF-alpha production in human monocytic cells (THP-1)More data for this Ligand-Target Pair
![](/img/powered_by_small.gif)